JUL 22·SEC EDGARLow
Herrmann Ken sold $119K of AKTS
Herrmann Ken sold 4,856 shares of Aktis Oncology, Inc. (AKTS) at $24.56 ($0.12M total) across 2 trades on 2026-07-20.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$AKTS
Aktis Oncology, Inc.
Price · $AKTSvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AKTS in the last 7 days.
Top stories · $AKTSMore →
JUL 10·SEC EDGAR
Ron-Bigger Shulamit sold $1.4M of AKTS
Ron-Bigger Shulamit (Chief Operating Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.75 ($27.13–$28.75, $1.39M total) across 3 trades on 2026-07-08.
JUL 10·SEC EDGAR
Czibere Akos sold $1.4M of AKTS
Czibere Akos (Chief Medical Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.77 ($27.13–$28.71, $1.39M total) across 3 trades on 2026-07-08.
AKTS sentiment & insider activity
Recent AKTS coverage spans insider activity and financial news.
In the last 30 days, AKTS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($197K). The most active reporter was Herrmann Ken with 3 filings.
What's driving AKTS
This is a routine insider sale with no stated 10b5-1 plan; it may slightly affect sentiment but is unlikely to change fundamentals.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
Insider open-market selling by a top executive can modestly pressure sentiment, but it is not evidence of fundamental deterioration by itself.
Insider buying combined with positive regulatory news suggests potential upside for Aktis Oncology (AKTS). The stock's bullish sentiment indicates increased investor confidence.
Aktis Oncology's FDA clearance for IND applications of AKY-2519 is a positive development, potentially accelerating its clinical trial timeline and future revenue streams.
alphai scores every news story that mentions AKTS with an AI model for sentiment and relevance, and aggregates insider trades from Aktis Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AKTS
Score
Herrmann Ken sold $119K of AKTS
Herrmann Ken sold 4,856 shares of Aktis Oncology, Inc. (AKTS) at $24.56 ($0.12M total) across 2 trades on 2026-07-20.
1 min readRon-Bigger Shulamit sold $1.4M of AKTS
Ron-Bigger Shulamit (Chief Operating Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.75 ($27.13–$28.75, $1.39M total) across 3 trades on 2026-07-08.
1 min readCzibere Akos sold $1.4M of AKTS
Czibere Akos (Chief Medical Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.77 ($27.13–$28.71, $1.39M total) across 3 trades on 2026-07-08.
2 min read5 Healthcare Stocks Insiders Are Buying
The article highlights five healthcare stocks that insiders are actively buying, indicating potential confidence in their future performance. It specifically details Aktis Oncology (NASDAQ:AKTS) as one such company, noting a raised price target from an analyst and recent FDA clearance for a Phase 1b trial of its investigational miniprotein radioconjugate. The piece also includes an extended advertisement for an AI stock, separate from the healthcare stock analysis.
3 min read
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology announced that the FDA cleared Investigational New Drug (IND) applications for AKY-2519, a miniprotein radioconjugate targeting B7-H3, enabling a Phase 1b clinical trial to begin in mid-2026. The company also provided business updates, including the Fast Track designation for its lead candidate AKY-1189, and reported financial results for 2025, showing increased R&D expenses and a net loss of $63.7 million. With a pro forma cash position of $562.1 million after its January 2026 IPO, Aktis anticipates funding operations into 2029.
4 min read
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
In the past week, significant insider buying occurred at W.R. Berkley Corp. (NYSE: WRB), Alumis Inc. (NASDAQ: ALMS), and Aktis Oncology Inc. (NASDAQ: AKTS). A beneficial owner continued to increase their stake in W.R. Berkley, while public offerings for Alumis and Aktis Oncology also attracted insider purchases. These transactions are often seen as a positive signal, as insiders typically buy shares when they anticipate a rise in stock price.
3 min read